Cel-Sci Corp of Virginia and Alpha-1 Biomedicals Inc of Maryland in the USA have commenced a clinical study of HGP-30, a potential vaccine for HIV infection. 15 healthy subjects, who took part in a safety study of HGP-30 three to four years ago, will participate in the new study, according to the two firms.
The vaccine has already been tested in two clinical trials with HIV-negative volunteers in California and the UK. Viral Technologies, a joint venture of Cel-Sci and Alpha 1, owns all rights to HGP-30.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze